PI3K/Akt/mTOR Pathway and Its Role in Cancer Therapeutics: Are We Making Headway?
Authors:
Top Cited Papers
Open Access
- 24 March 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 819128
Abstract
Cancer is a severe public health issue that is a leading cause of mortality globally. It is also an impediment to improving life expectancy worldwide. Furthermore, the global burden of cancer incidence and death is continuously growing. Current therapeutic options are insufficient for patients, and tumor complexity and heterogeneity necessitate customized medicine or targeted therapy. It is critical to identify potential cancer therapeutic targets. Aberrant activation of the PI3K/AKT/mTOR pathway has a significant role in carcinogenesis. This review summarized oncogenic PI3K/Akt/mTOR pathway alterations in cancer and various cancer hallmarks associated with the PI3K/AKT/mTOR pathway, such as cell proliferation, autophagy, apoptosis, angiogenesis, epithelial-to-mesenchymal transition (EMT), and chemoresistance. Importantly, this review provided recent advances in PI3K/AKT/mTOR inhibitor research. Overall, an in-depth understanding of the association between the PI3K/AKT/mTOR pathway and tumorigenesis and the development of therapies targeting the PI3K/AKT/mTOR pathway will help make clinical decisions.Keywords
Funding Information
- National Natural Science Foundation of China (81660755)
- Science and Technology Planning Project of Shenzen Municipality (JCYJ20170307160524377, JCYJ20190808162605484)
This publication has 122 references indexed in Scilit:
- Mutations in Critical Domains Confer the Human mTOR Gene Strong Tumorigenicity*Journal of Biological Chemistry, 2013
- Disruption of PH–kinase domain interactions leads to oncogenic activation of AKT in human cancersProceedings of the National Academy of Sciences, 2012
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- The functions and regulation of the PTEN tumour suppressorNature Reviews Molecular Cell Biology, 2012
- TGF-β-induced activation of mTOR complex 2 drives epithelial–mesenchymal transition and cell invasionJournal of Cell Science, 2012
- Apoptosis in cancer: from pathogenesis to treatmentJournal of Experimental & Clinical Cancer Research, 2011
- PTEN loss in the continuum of common cancers, rare syndromes and mouse modelsNature Reviews Cancer, 2011
- PI3K/AKT/mTOR Pathway in AngiogenesisFrontiers in Molecular Neuroscience, 2011
- Mammalian Target of Rapamycin (mTOR): Conducting the Cellular Signaling SymphonyJournal of Biological Chemistry, 2010
- Angiogenesis in cancerVascular Health and Risk Management, 2006